Daily Stock Opinions and Ratings

Opinions

Cameron Hurst Celgene Corp CELG-Q DON'T BUY Oct 10, 2018

They have a good cash float, which will lead to a share buyback, he feels. He sees resistance at $90-$100, which will be tough to battle through. He would suggest taking a loss if you hold this one, because the future capex requirements will be more expensive as interest rates rise. He would prefer IHI-N if you like the healthcare space as he does.

Cameron Hurst

Unlock Rating

$84.230

Stock price when the opinion was issued

Consumer Products

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

SELL

Having issues in terms of competition. They wanted to merge with Bristol. She doesn't think the combination makes it a better company. She would sell on the announcement (as the stock lifted).

PAST TOP PICK

(A Top Pick Mar 20/18, Down 0.2%) It was one of his hopes in the medical area for great growth. They are being acquired. He is going to keep holding it.

PAST TOP PICK

(A Top Pick May 30/18, Up 22%) They have a lot of new products in their patent portfolio. They are being acquired. It would be a nice speculative holding in the marketplace when it closes.

BUY

Bistol-Myers bought it which is good news for Celgene holders.

PAST TOP PICK

(A Top Pick Mar 21/18, Up 10%) Sold it because it's getting taken out by Bristol Myers.

DON'T BUY

Heading into the election cycle, pharma will be under pressure. He prefers being into medical devices. He has a hard time being excited about either CELG or BMY, especially if the market is currently jittery. (Analysts’ price target is $100.33)

COMMENT

He started buying BMY-N ahead of the merger discussions with CELG-Q. If the merger fails, holding the buyer is safer as arbitragers unwind hedges. The combined company would be a good cash flow generator, which would help internal growth and debt pay down.

PAST TOP PICK

(A Top Pick Oct 22/18, Up 25%) The Bristol acquisition was perfect. CELG boasts strong competitive barriers to their products and their product pipeline will pleasantly surprise the market. He's not worried about the US election and the negative effect on US healthcare; in fact, he loves buying stocks when others fear or hate them.

SELL

He sold out because it's going to be merged with Bristol Myers, they received full value, and there's always deal risk. Celgene owners may get a premium if 3 drugs come to market and exceeded certain thresholds. This is a side bet, and not the way he likes to invest.

PAST TOP PICK

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Cameron Hurst Celgene Corp CELG-Q DON'T BUY Oct 10, 2018

You might be interested:

Celgene Corp(CELG-Q)

Celgene Corp(CELG-Q)

Celgene Corp(CELG-Q)

Celgene Corp(CELG-Q)

Celgene Corp(CELG-Q)

Celgene Corp(CELG-Q)

Celgene Corp(CELG-Q)

Celgene Corp(CELG-Q)

Celgene Corp(CELG-Q)

Celgene Corp(CELG-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights